ABSI

ABSI

Absci Corp

Absci Corporation develops antibody therapeutics using AI and synthetic biology to streamline drug discovery. Its pipeline includes candidates for inflammatory bowel disease, androgenic alopecia, and oncology, supported by collaborations with various institutions.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$398today

Score Overview

1 Year
Score
Net Growth-2.82%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-34.43%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score2.2
Net Growth-17.31%
Net Trend20%
Net Income Consistencyโ€”
Rev Growth-61.61%
Rev Trend20%
Revenue Consistencyโ€”
All Time
Score
Net Growth-17.31%
Net Trend20%
Net Income Consistency
Rev Growth-61.61%
Rev Trend20%
Revenue Consistency

See the full market ranking โ†’

Absci Corp fundamental performance

Between 2021 and 2025, revenue declined from $ 4M to $ 2M and net income went from -$ 100M to -$ 115M. Revenue increased in 20% of the years measured; net income in 20%.

Absci Corp currently holds a 5-year HDB Score of 2.2 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 9.50โ€”
1 Year2025-08-12
$ 2.97219.87%
5 Years2021-08-12
$ 23.85-60.17%
All Time2021-07-22
$ 21.59-56.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 1M-$ 118M$ 125M
2025$ 2M-$ 115M$ 144M
2024$ 4M-$ 103M$ 112M
2023$ 5M-$ 110M$ 97M
2022$ 5M-$ 104M$ 164M
IPO2021$ 4M-$ 100M$ 252M

Explore beyond ABSI

You're looking at Absci Corp. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies